Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428468 | 0.92 | S1PR1 (0.54) | S1PR1S1PR3KCNH2 | |
| SCHEMBL3426943 | 0.91 | S1PR1 (0.43) | S1PR1S1PR3S1PR5KCNH2 | |
| SCHEMBL3423106 | 0.91 | S1PR1 (0.64) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL3430744 | 0.90 | S1PR1 (0.55) | S1PR1S1PR3KCNH2 | |
| SCHEMBL3429275 | 0.89 | S1PR1 (0.43) | S1PR1S1PR3KCNH2 | |
| SCHEMBL3428998 | 0.87 | S1PR1 (0.55) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3428752 | 0.85 | S1PR1 (0.47) | S1PR1S1PR5S1PR4 | |
| SCHEMBL945267 | 0.85 | S1PR1 (0.40) | S1PR1 | |
| SCHEMBL3431635 | 0.83 | S1PR1 (0.43) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3428963 | 0.83 | CPT2 (0.40) | S1PR1S1PR3S1PR5S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.